Validation of the Steroid PRO Across International Gastroenterology, Respiratory, and Dermatology Departments: Evaluating the Effects of Steroids on Patients' Health-Related Quality of Life

Speaker(s)

Sweeny AM1, Bridgewater S1, Orme J1, Sharp M2, Sattui S3, Richards P1, Silverthorne C1, Arthurs E4, Creed T4, Raymer J5, Osborne G4, Dunhill G4, Dawson J6, Dures E1, Goodman S7, Hill C8, Mackie S9, Robson J10
1University of the West of England, Bristol, Bristol, UK, 2Johns Hopkins School of Medicine, Baltimore, MD, USA, 3University of Pittsburgh, Pittsburgh, PA, USA, 4University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, Bristol, UK, 5Oxford University Innovation, Oxford, UK, 6University of Oxford, Oxford, Oxfordshire, UK, 7Hospital for Special Surgery, New York, NY, USA, 8University of Adelaide, Adelaide, SA, Australia, 9University of Leeds, Leeds, UK, 10University of West England, Bristol, UK

Presentation Documents

OBJECTIVES: The Steroid PRO is a treatment-specific patient-reported outcome measure designed and validated for patients with rheumatic conditions to assess the impact of glucocorticoids on health-related quality of life. This study examined the face and content validity, as well as the feasibility, of the Steroid PRO among patients and clinicians in dermatology, respiratory/pulmonology, and gastroenterology specialties.

METHODS: Semi-structured online or face-to-face interviews were conducted with patients and healthcare professionals (HCPs) from the United Kingdom and the United States. Adapted cognitive interviewing techniques were used in conjunction with a structured data collection tool. Purposive sampling ensured a diverse range of participants, covering various demographics and disease characteristics for patients and different roles for healthcare professionals.

RESULTS: Forty-five cognitive interviews were conducted, including 31 with patients and 14 with healthcare professionals (HCPs). The participants represented a diverse group with inflammatory lung, bowel, and skin diseases. For face validity, 97% (30 out of 31) of patients and 100% (14 out of 14) of HCPs found the Steroid PRO to be either "relevant" or "very relevant" to them and their conditions. Regarding feasibility, 97% (30 out of 31) of patients and 100% (14 out of 14) of HCPs reported that the Steroid PRO was either "easy" or "very easy" to complete. Patients highlighted that the four domains of the Steroid PRO (Social Impact, Impact on Appearance, Psychological Impact, and Treatment Concerns) resonated with their experiences, feeling validated by seeing their concerns addressed.

CONCLUSIONS: The Steroid PRO shows strong face and content validity, as well as feasibility, among patients with inflammatory lung, bowel, and skin diseases, and their healthcare professionals. Its use in clinical practice and research effectively captures the patient’s perspective on the impact of glucocorticoids.

Code

CO104

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment

Disease

Drugs, Gastrointestinal Disorders, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Sensory System Disorders (Ear, Eye, Dental, Skin)